BioCentury | Jan 12, 2021
Finance

Jan. 11 Quick Takes: Megarounds for Valo, Visen; plus NuProbe, Sensei

...other existing investors plus new institutional investors including Invus Public Equities, HBM Healthcare Investments, Atinum Investment and Mirae Asset Capital...
BioCentury | Jan 6, 2021
Finance

Senti banks $105M series B as Bayer continues to show enthusiasm for gene and cell therapy biotechs

...with the pharma’s future priorities.Other new investors in the series B included Matrix Partners China, Mirae Asset Capital...
BioCentury | Dec 11, 2019
Financial News

Dec. 10 Financial Quick Takes: Inscripta, Aurinia, Akeso, Ribo, Hummingbird, ImmunOs, Peregrine

...million. Existing investors Heritas Capital and Seeds Capital, as well as new investors Delian Capital, Mirae Asset Capital...
BioCentury | Oct 4, 2019
Emerging Company Profile

Arcellx debuts with $85M, tech for adapting CAR Ts

...and non-oncology indications. Other new investors in the series B included Mirae Asset Venture Investment, Mirae Asset Capital...
...A/S, SR One, NEA, Takeda Ventures, Aju IB Investment, Quan Capital, Mirae Asset Venture Investment, Mirae Asset Capital...
BioCentury | May 7, 2019
Financial News

Liver cell therapy company Promethera grows Asian investor base with D round

...Capital Partners co-led the round. New investors include Japan’s Medipal Holdings Corp., Korean mutual fund Mirae Asset Capital...
BioCentury | Apr 30, 2019
Finance

How Nextech-led round will help Vividion to POC

...J&J’s life science incubator JLABS. New investors BVF Partners, Casdin Capital, Mubadala Ventures, Trinitas Capital, Mirae Asset Capital...
Items per page:
1 - 6 of 6
BioCentury | Jan 12, 2021
Finance

Jan. 11 Quick Takes: Megarounds for Valo, Visen; plus NuProbe, Sensei

...other existing investors plus new institutional investors including Invus Public Equities, HBM Healthcare Investments, Atinum Investment and Mirae Asset Capital...
BioCentury | Jan 6, 2021
Finance

Senti banks $105M series B as Bayer continues to show enthusiasm for gene and cell therapy biotechs

...with the pharma’s future priorities.Other new investors in the series B included Matrix Partners China, Mirae Asset Capital...
BioCentury | Dec 11, 2019
Financial News

Dec. 10 Financial Quick Takes: Inscripta, Aurinia, Akeso, Ribo, Hummingbird, ImmunOs, Peregrine

...million. Existing investors Heritas Capital and Seeds Capital, as well as new investors Delian Capital, Mirae Asset Capital...
BioCentury | Oct 4, 2019
Emerging Company Profile

Arcellx debuts with $85M, tech for adapting CAR Ts

...and non-oncology indications. Other new investors in the series B included Mirae Asset Venture Investment, Mirae Asset Capital...
...A/S, SR One, NEA, Takeda Ventures, Aju IB Investment, Quan Capital, Mirae Asset Venture Investment, Mirae Asset Capital...
BioCentury | May 7, 2019
Financial News

Liver cell therapy company Promethera grows Asian investor base with D round

...Capital Partners co-led the round. New investors include Japan’s Medipal Holdings Corp., Korean mutual fund Mirae Asset Capital...
BioCentury | Apr 30, 2019
Finance

How Nextech-led round will help Vividion to POC

...J&J’s life science incubator JLABS. New investors BVF Partners, Casdin Capital, Mubadala Ventures, Trinitas Capital, Mirae Asset Capital...
Items per page:
1 - 6 of 6